BREAKING: President Donald Trump is set to announce a controversial connection between Tylenol use during pregnancy and autism risk at a press conference scheduled for 4:00 PM local time today (2000 GMT). This announcement follows ongoing debates surrounding autism’s causes, which many experts attribute primarily to genetic factors.
Trump’s announcement, which he described as “one of the most important news conferences I’ll ever have,” comes as pressure mounts from his administration’s health chief, Robert F. Kennedy Jr.. Known for his anti-vaccine stance, Kennedy has promised to unveil findings concerning autism’s origins by September 2025. Speaking to a large audience at a memorial for activist Charlie Kirk, Trump teased, “I think we found an answer to autism, how about that?”
However, the administration’s focus on autism and Tylenol has drawn significant criticism from the medical community. The American College of Obstetricians and Gynecologists has classified Tylenol as one of the safest pain relief options during pregnancy, while also warning against its long-term use. Experts caution that claims linking Tylenol to autism lack conclusive evidence.
In a statement, Karoline Leavitt, White House Press Secretary, urged the media to withhold judgment until the details of the announcement are revealed. She stated, “Everyone in this room needs to tone down the judgment before you even hear what people are going to say.”
Reports suggest that the announcement may also include discussions around a potential autism treatment involving the drug leucovorin, which has shown promise in preliminary trials but requires further research. A literature review published last month indicated a possible link between Tylenol exposure and autism; however, conflicting studies warn against overinterpreting these findings.
Psychiatric epidemiologist David Mandell from the University of Pennsylvania noted that the risks associated with Tylenol use are likely lower than the risks posed by untreated infections during pregnancy. He emphasized that comprehensive studies on genetic and environmental factors shaping autism require extensive funding and time.
The Coalition of Autism Scientists has condemned the administration’s approach, labeling it “highly irresponsible.” They expressed concerns that Secretary Kennedy’s announcement could cause widespread confusion and fear among the public regarding autism.
As the clock ticks down to the press conference, the scientific community watches closely, raising questions about the implications of this announcement and the potential impact on public perception of autism and its causes. Stay tuned for updates on this developing story.
